Research Project on the Prevention and Control of Clonorchiasis (Subproject 1: Comparative Study on the Therapeutic Efficacy of Anthelmintic Drugs against Clonorchiasis)

Start Date01 Sep 2025

Sponsor / Collaborator

The People's Hospital of Guangxi Zhuang Autonomous Region

NCT07074444

/ RecruitingPhase 4IIT

Albendazole, Tribendimidine, and Praziquantel for Clonorchiasis in Guangxi: A Randomized Controlled Trial Comparing Efficacy and Safety

The goal of this clinical trial is to evaluate and compare the efficacy and safety of three commonly used antiparasitic drugs-albendazole, tribendimidine, and praziquantel-for the treatment of clonorchiasis, a liver fluke infection acquired by consuming raw or undercooked freshwater fish.
This study aims to answer the following primary questions:
How effective is each drug in achieving parasitological cure, as measured by clearance of Clonorchis sinensis eggs in stool? What types and frequencies of adverse events are associated with each treatment?
Participants in this randomized, open-label trial will:
Be randomly assigned to receive one of the three study drugs according to a predefined dosing regimen.
Provide stool samples before treatment and at follow-up to assess for Clonorchis sinensis eggs.
Undergo a second round of the same treatment regimen and repeated stool examination if eggs are still detected after the first course.
Attend follow-up visits, which include symptom assessment, blood tests (hematology and liver function), and abdominal ultrasonography focusing on hepatobiliary changes.
Report any side effects, discomfort, or adverse reactions experienced during or after treatment.
The findings from this study will help inform optimal therapeutic strategies for clonorchiasis in outpatient clinical settings.

Start Date22 Jul 2025

Sponsor / Collaborator

First Affiliated Hospital of Guangxi Medical University

[+1]

NCT07045493

/ Enrolling by invitationPhase 2IIT

Assessing Safety and Efficacy of Ivermectin and Albendazole Combination Therapy for Soil-transmitted Helminthiasis in Pre-school-aged Children (PSAC) in Bangladesh

Background (brief):
1. Burden:
Soil-transmitted helminth (STH) infections are a major public health problem, primarily affecting children. Although STH prevalence has decreased to 14% in Bangladesh, over 47 million preschool- and school-age children still live in high-risk areas.
2. Knowledge gap:
Albendazole shows 94-100% efficacy against A. lumbricoides but only 39-60% against T. trichuria. Ivermectin is also effective against hookworm and T. trichuria. Combining ivermectin with albendazole may be more effective than using either drug alone, but this combined therapy for STH has not yet been studied in Bangladesh.
3. Relevance:
STHs significantly impact children's nutrition, hindering health, growth, cognition, and learning. The national deworming program achieved 98.3% treatment coverage, but only 76.2% of PSAC were dewormed using self-prescribed medicines.
Hypothesis (if any):
The combination therapy of Albendazole and Ivermectin is more effective than Albendazole alone for treating soil-transmitted helminths in preschool-age children in Bangladesh
Objectives:
1. To compare the safety and efficacy of Albendazole and Ivermectin combination therapy with Albendazole monotherapy in preschool-aged children
2. To evaluate post-treatment egg reduction rates for various helminths at different time points
3. To determine the median time to re-infection following different anti-helminth interventions for various STH
Methods:
This Phase IIa single-blinded, randomized controlled trial will evaluate the safety and efficacy of ivermectin and albendazole combination therapy versus standard albendazole monotherapy for STH in 2-5 years in rural Belkuchi, Sirajganj. A total of 110 PSAC with confirmed STH will be randomly assigned to two treatment arms. Field activities and laboratory analysis will use the Kato-Katz technique for microscopic examination.
Outcome measures/variables:
* Evaluate the safety and efficacy of ivermectin and albendazole combination therapy for STH
* Evaluate the statistically significant impact on patient clinical outcomes, cure rate, and egg reduction rate
* Correlate changes in Cure Rate and Egg Reduction Rate for different STH at various time points

Start Date10 Jul 2025

Sponsor / Collaborator

International Centre for Diarrhoeal Disease Research, Bangladesh

[+1]

100 Clinical Results associated with Albendazole

100 Translational Medicine associated with Albendazole

100 Patents (Medical) associated with Albendazole

8,557

Literatures (Medical) associated with Albendazole

01 Apr 2026·VETERINARY PARASITOLOGY

Pseudocapillaria tomentosa infections in laboratory larval and Adult Zebrafish (Danio rerio): Development and advances in an in vivo anthelmintic drug discovery model

Article

Author: Kent, Michael L ; Sharpton, Thomas J ; Leong, Connor ; Kyne, Aisling ; Scanlon, Ruby

Zebrafish (Danio rerio) are a widely used biomedical model and offers powerful high-throughput screening capabilities for assessing chemical bioactivity. We have previously employed adult zebrafish infected with the intestinal nematode Pseudocapillaria tomentosa to investigate nematode-microbiome interactions, nematode-promoted intestinal neoplasia, and anthelmintic drug discovery. Here we transition this model to a larval zebrafish infection infection to enable larger-scale experimentation and ultimately accelerate anthelmintic discovery. Infection conditions were optimized across 5-30 days post fertilization (dpf). The 30 dpf larvae exhibited the most robust and reproducible infections in multi-well formats, as well as the highest survival relative to younger stages. We described worm development from hatching through larval progression and maturation, addressing a major gap in foundational data with fish capillarids. Using in vitro-hatched larvae and infected larval and adult zebrafish, we documented developmental trajectories from 1 to 37 days post-exposure. Change-point analysis identified putative ecdysis transitions at the following worm lengths (mm): L1/L2 = 0.220, L2/L3 = 0.571, L3/L4 = 1.174, and L4/L5 = 1.584. Finally, we demonstrated proof-of-concept for anthelmintic screening by exposing fish to larvated eggs in the presence of emamectin benzoate (macrocyclic lactone) or fenbendazole (benzimidazole). Both compounds reduced worm burdens after 3 days, with the strongest effects at higher concentrations (0.7 µM emamectin benzoate; 0.3 µM fenbendazole). Together, these findings establishes a proof of concept for larval zebrafish infection platform which bridges the gap between in vitro and mammalian in vivo assays, enabling scalable, efficient, and biologically relevant screening for anthelmintic drug discovery.

01 Apr 2026·JOURNAL OF COLLOID AND INTERFACE SCIENCE

Core-shell heterostructured nanozyme for alveolar echinococcosis treatment via targeted electron transfer and catalytic reactive oxygen species generation

Article

Author: Cui, Yaqi ; Li, Jun ; Alifu, Nuernisha ; Dong, Biao ; Zhang, Wenbao ; Ma, Jiaqi ; Zhao, Zenghao ; Zhang, Chi ; Wang, Meiling

Alveolar echinococcosis (AE), a severe parasitic disease, poses a significant therapeutic challenge due to the limitations of surgery and albendazole chemotherapy, particularly the difficulty in achieving targeted drug delivery and disrupting the robust structure of the protoscoleces (PSCs). This study introduces a novel therapeutic strategy of "targeted binding-electron transfer (ET)-osmotic disruption" to address these challenges. We designed a core-shell heterostructure nanoplatform (FZ) composed of a magnetite (Fe₃O₄) nanozyme core and a zinc oxide (ZnO) semiconductor shell. This architecture strategically overcomes the key limitations of nanozymes, namely instability and insufficient catalytic activity. The ZnO shell physically protects the Fe₃O₄ core from oxidation and dissolution, thereby preserving the active electron-donating valence state (Fe²⁺) and ensuring long-term ET capability. Furthermore, the heterostructure enhances the peroxidase-like catalytic activity, with the optimized FZ-2 exhibiting a 41.8% increase over pristine Fe₃O₄. By modulating the surface charge, the nanoplatform achieves specific targeting and adsorption onto the negatively charged PSCs' surface. The subsequent interfacial ET from FZ-2 disrupts the PSCs' membrane potential, leading to lethal osmotic imbalance and a high efficacy (98%) in inducing PSCs death. This work not only provides a potent nanomedicine for AE but also establishes a pioneering ET-based therapeutic paradigm for treating diseases with complex multicellular barriers.

01 Mar 2026·BIOORGANIC CHEMISTRY

Effect of apatinib on albendazole metabolism in vitro and in vivo

Article

Author: Xia, Hailun ; Fu, Haoxin ; Cao, Lu ; Lin, Weihong ; Li, Ruibin ; Wang, Peiqi ; Xu, Ren-Ai ; Wu, Jun

Albendazole is a broad-spectrum antiparasitic benzimidazole and has potential for the treatment of tumors. The aim of this study was to investigate the potential inhibitory effects of 77 drugs on the metabolism of albendazole, and further to elaborate the inhibitory mechanism of apatinib on albendazole metabolism in vitro and in vivo, where the concentrations of albendazole and its metabolites were detected using an ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) assay. In vitro results showed that 10 drugs inhibited albendazole metabolism by more than 80%, with the half-maximal inhibitory concentrations (IC₅₀) of apatinib in rat liver microsomes (RLM), human liver microsomes (HLM) and recombinant human CYP3A4 (rCYP3A4) being 0.47, 5.53 and 2.01 μM, respectively. Moreover, the inhibition of albendazole by apatinib was non-time-dependent. In addition, the inhibitory mechanisms were mixed consisting of non-competitive and un-competitive for RLM, and competitive and non-competitive for HLM and rCYP3A4. Pharmacokinetic parameters in Sprague-Dawley rats showed that apatinib caused significant increases in AUC_(0-t), AUC_(0-∞), C_max, T_max and t_1/2, while a significant decrease in CL_z/F for albendazole. For the metabolites albendazole sulfoxide and hydroxyalbendazole, apatinib caused significant increases in AUC_(0-t), AUC_(0-∞), and T_max, while a significant decrease in CL_z/F. In summary, apatinib could inhibit the metabolism of albendazole in vitro and in vivo, so albendazole should be closely monitored for adverse effects when used in combination with apatinib and discontinued if necessary.

News (Medical) associated with Albendazole

17 Nov 2025

·www.merck.com

Merck Commemorates 5 Billion Mectizan® Treatments Donated Over 38 Years

November 17, 2025 6:45 am EST Extension of Mectizan Donation for Triple Therapy Advances Fight Against Lymphatic Filariasis Through 2030 RAHWAY, N.J., November 17, 2025 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is extending the donation of up to 100 million ivermectin treatments annually through 2030, reinforcing its longstanding commitment to the global elimination of lymphatic filariasis (LF) through the World Health Organization’s (WHO) recommended triple drug therapy strategy. This renewed pledge is driven by the strong progress reported by the WHO, including the milestone achievement of Timor-Leste becoming the first country in 2024 to eliminate LF using this approach. “By extending our commitment, we aim to ensure that national LF elimination programs in endemic countries continue to have reliable access to the treatments needed to protect vulnerable populations and strengthen health systems,” said Robert M. Davis, chairman and chief executive officer, Merck. “This work is essential to achieving the WHO’s Neglected Tropical Disease Road Map, which targets global elimination by 2030.” Merck’s donation supports the co-administration of ivermectin (Mectizan), diethylcarbamazine and albendazole — commonly referred to as “triple therapy” — in countries where onchocerciasis (river blindness) is not co-endemic. LF, also known as elephantiasis, is a mosquito-borne parasitic disease that severely damages the lymphatic system. It can lead to extreme swelling of the limbs and genitals, resulting in lifelong disability, pain and social stigma. “WHO is deeply grateful to Merck for its generosity and solidarity with communities affected by LF," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “In a time of declining resources for global health, in-kind commitments and public-private partnerships are more important than ever. These partnerships have brought us so far in the fight against LF and are the foundation for eliminating many neglected tropical diseases. Together, we can finish the job.” Merck first pledged in 1987 to provide Mectizan for the treatment of river blindness, a leading cause of preventable blindness worldwide, transmitted through the bite of black flies that breed near fast-flowing streams and rivers, for as much as needed, as long as needed. The Mectizan Donation Program was established that same year as an independent body to oversee Merck’s donation. In 1998, the program expanded to support LF elimination in African countries and Yemen, where LF and river blindness are co-endemic. In 2017, Merck further strengthened its support by adding up to 100 million additional treatments annually through 2025 to accelerate LF elimination with triple therapy. Research shows that the use of triple therapy reduces the parasites in the blood significantly longer than two-drug regimens, requiring fewer number of treatment rounds needed to interrupt LF transmission. The new five-year extension builds on demonstrated success in countries implementing triple therapy to eliminate LF. Once endemic in 72 countries, LF has now been eliminated as a public health threat in 21 countries across five WHO regions, with the disease remaining endemic and requiring mass treatment in just 39 countries. To date, Merck has donated more than 5 billion Mectizan treatments to 62 countries, resulting in the successful elimination of river blindness or LF in nine countries by incorporating Mectizan into national public health strategies. In addition, more than 340 million people no longer require treatment in subnational regions of several African countries as disease transmission is believed to have been eliminated. About the Mectizan® Donation Program The Mectizan Donation Program (MDP) was established at the Task Force for Global Health in 1987 to provide medical, technical and administrative oversight of the donation of MECTIZAN® by Merck for the treatment of onchocerciasis. In 1998, the MDP expanded its mandate to include coordination of the donation of albendazole by GSK to be distributed in conjunction with Mectizan for the elimination of lymphatic filariasis in onchocerciasis co-endemic areas. In 2017 the mandate was further extended to oversee the donation of Mectizan for IDA in eligible countries. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). Media Contacts: John Cummins john.cummins2@merck.com Ned Ehrbar ned.ehrbar@merck.com Investor Contacts: Peter Dannenbaum (732) 594-1579 Steven Graziano (732) 594-1583

04 Sep 2025

·www.globenewswire.com

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

Catalyst for Advancing Discussions with Pharmaceutical Companies that have Expressed Interest in ART27.13 for CACS Consistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed Across Treated Patients including +6.4% Mean Weight Gain at 12 Weeks vs −5.4% Mean Weight Loss on Placebo Safety Results Showed ART27.13 was Well Tolerated Sept. 03, 2025 -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced highly encouraging interim results from its Phase 2 Cancer Appetite Recovery Study (CAReS) trial with ART27.13, the Company’s peripherally acting cannabinoid receptor agonist for the treatment of cancer anorexia-cachexia syndrome (CACS). Affecting up to 80% of people living with cancer, CACS is marked by loss of appetite, weight loss, and breakdown of muscle and fat. This leading cause of death in cancer patients has no FDA-approved treatment. The CAReS interim data comparing ART27.13 to placebo supports acceleration of the Company’s partnering initiatives with its lead clinical program. Weight Gain: Patients escalated to the 1300 microgram dose achieved a +6.38% mean weight gain after 12 weeks, compared to a -5.42% average loss on placebo. The maximum gain observed was +18.5% on ART27.13 versus only +0.4% on placebo. Lean Body Mass: At one month, patients treated with ART27.13 experienced a +4.23% increase in lean body mass, while placebo patients lost -3.15%. Activity: Patients receiving treatment showed improvements in activity scores and in moderate and vigorous activity, the latter being an endpoint that may be required by regulators for drug approval. Safety: ART27.13 was well tolerated. The most common adverse events were mild or moderate. No new safety signals were observed and interim safety results were consistent with Phase 1 of CAReS. Barry Laird, Professor of Palliative Medicine, Oslo University Hospital - Radium Hospital and University of Oslo, Norway, and Chief Investigator in CAReS said, "The findings from the CAReS Phase 2 interim analysis build on the strong safety profile and signal from the Phase 1 trial and provide encouraging data supporting efficacy of ART27.13 on weight and physical activity in patients with advanced cancer.” The Phase 2 CAReS study is evaluating ART27.13 as a once-daily oral treatment aimed at improving weight, appetite, activity, and quality of life in cancer patients who had lost a minimum of 5% of their body weight in the prior six months. Effectiveness was measured by changes in lean body mass, weight, appetite, and activity over 12 weeks and at a 30-day follow-up. Activity and quality of life were assessed using wearable monitors and standardized questionnaires, while safety was closely tracked through adverse event reporting, laboratory tests, vital signs, visual analogue scales, and ECGs. In the interim analysis, 18 evaluable patients—primarily with lung and gastrointestinal cancers not receiving cyclic chemotherapy—were included. After 12 weeks of treatment in patients who titrated to the top dose evaluated of 1300 micrograms (n=5), ART27.13 demonstrated compelling increases in mean body weight of 6.38% (Standard Deviation or SD 9.50) compared to patients on placebo (n=6) who lost -5.42% (SD 8.17). The maximum weight gain in the ART27.13 group reached 18.5%, versus only 0.4% in placebo. The maximum weight loss in the placebo arm was -17.4%, compared to just -3.0% in the ART27.13 group. Additional benefits were seen in lean body mass, with a +4.23% increase (SD 5.37) in the treatment group versus a -3.15% loss (SD 4.89) in placebo at one month, as well as qualitative improvements in total and weekly activity scores. Safety results were consistent with prior findings. Among the 32 participants enrolled in the CAReS Phase 2 trial to date, 7 patients (22%) experienced adverse events that may be related to ART27.13. All were mild or moderate, with the exception of a single case of severe malaise, and no drug-related serious adverse events were reported. These data are aligned with safety outcomes observed in Phase 1 of CAReS, supporting ART27.13’s overall favorable tolerability and acceptable safety profile. “These data represent a reassuring and convincing drug effect for the highest dose of ART27.13 tested,” stated Steven Reich, MD, Chief Medical Officer of Artelo. “For patients facing the devastating effects of cancer anorexia and cachexia, we believe these findings are particularly promising, especially for the Phase 2 protocol patients that had intra-patient dose-escalation. With these interim results, we are evaluating plans to advance the ART27.13 program by starting patients at the highest dose, which has the greatest treatment effect and acceptable safety.” Gregory D. Gorgas, President and CEO of Artelo, commented, “Based on the strength of this data and the recently announced Notice of Allowance for the patent application covering our intended commercial formulation through 2041, we are rapidly accelerating our licensing strategy as the most value-accretive path forward. We are in the process of sharing these results with global and regional pharmaceutical companies already familiar with ART27.13 who were awaiting this randomized data from the CAReS trial. Through this targeted effort we aim to speed development and maximize value for our shareholders.” ART27.13 is a novel benzimidazole derivative being developed as a once-daily, orally administered agent selectively targeting peripheral CB1 and CB2 receptors, with the potential to improve body weight, appetite, muscle degeneration, and quality of life in cancer patients. Initially developed by AstraZeneca plc, ART27.13 has been in seven clinical studies with over 280 participants. A statistically significant and dose-dependent increase in body weight was observed in people with back pain who were otherwise healthy. Importantly, the drug enables systemic metabolic effects while minimizing central nervous system-mediated toxicity. Having completed a Phase 1 study in cancer patients where ART27.13 demonstrated an excellent safety profile, Artelo is conducting a Phase 2 trial as a supportive care therapy for cancer patients suffering from anorexia and weight loss. Currently, there is no FDA approved treatment for cancer anorexia cachexia syndrome. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of the Company’s lead clinical program, ART27.13, in patients with cancer anorexia and weight loss. Cancer-related anorexia, or the lack or loss of appetite in the person with cancer, may result from the cancer and/or its treatment with radiation or chemotherapy. It is common for people with cancer to lose weight. Anorexia and the resulting weight loss can affect a patient’s health, often weakening their immune system and causing discomfort and dehydration. A weight loss of more than 5% can predict a poor outcome for cancer patients and a lower response to chemotherapy. The Phase 1 portion of the CAReS study was designed to determine the most effective and safest initial dose of ART27.13 in the Phase 2 stage. The Phase 2 portion of the CAReS study is designed to determine estimates of activity of ART27.13 in terms of lean body mass, weight gain, and improvement of anorexia compared to placebo. Cancer Anorexia-Cachexia Syndrome (CACS) is a condition marked by loss of appetite, weight loss, and the breakdown of muscle and fat, affecting up to 80% of patients with advanced cancer- representing a greater than $3 billion addressable market. This loss of appetite, known as anorexia, may result from the cancer itself or from treatments such as radiation and chemotherapy. The resulting weight loss can weaken the immune system, cause discomfort and dehydration, and lower a patient’s ability to tolerate treatment. Losing more than 5% of body weight is associated with poorer outcomes and reduced response to chemotherapy. While drugs that stimulate appetite have been used to help manage cancer-related anorexia, there are currently no approved treatments in the US, UK, or EU for this condition. Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Complementing its scientific innovation, Artelo has adopted a forward-looking corporate finance initiative whereby it is deploying a portion of its excess capital into Solana under its digital asset treasury strategy. Led by an experienced executive team collaborating with world-class researchers and digital-asset technology partners, Artelo applies rigorous scientific, regulatory, commercial, and treasury management practices to maximize stakeholder value. The content above comes from the network. if any infringement, please contact us to modify.

Clinical Result

21 May 2025

·pharma.economictimes.indiatimes.com

196 Drug Samples Fail CDSCO Quality Test; One Deca-Durabolin Sample Flagged as Spurious

New Delhi: Drug regulators, during their monthly quality review, have identified around 196 drug samples as “ Not of Standard Quality ” (NSQ) and one sample as “spurious.” The drug alert issued by the Central Drugs Standard Control Organization ( CDSCO ) states that out of the 196 NSQ samples, 60 were identified by central drug laboratories, while the remaining 136 were flagged by state laboratories. In addition, one drug sample identified as spurious is a “ Nandrolone Decanoate Injection,” marketed as Deca-Durabolin —an anabolic steroid used for various medical conditions, including osteoporosis and anemia. According to a note from the Union Health Ministry , the spurious sample was picked from Bihar and “is manufactured by an unauthorized manufacturer using the brand name owned by another company.” In its alert, the CDSCO specified that the tested sample failed due to issues with the “Identification and Assay of Nandrolone Decanoate .” In India, “Deca-Durabolin 50 mg” is marketed by Ahmedabad-based Zydus Healthcare, following its acquisition of the brand from MSD (Merck Sharp & Dohme) in December 2016. The matter is currently under investigation, and the purported spurious drug is subject to the outcome of the inquiry. A drug is deemed spurious if it resembles another drug in a manner likely to deceive, or if it bears upon its label or container the name of another drug—among several other conditions detailed under Section 17-B of the Drugs and Cosmetics Act, 1940. Among the 60 NSQ samples flagged by central laboratories are Nimesulide and Paracetamol tablets manufactured by Pro-Pharma Care; Cefpodoxime Proxetil tablets by Sunvij Drugs; Ciprofloxacin tablets by Cadila Pharmaceuticals; and 57 other samples. The 136 NSQ samples identified by state laboratories include Glimepiride 1 mg and Metformin HCl 500 mg tablets manufactured by Surge Pharmaceuticals; Albendazole tablets by Samkem; and Oxfendazole and Ivermectin Bolus by Argon Remedies, among 133 other samples. The identification of drug samples as NSQ is based on the failure of the sample to meet one or more specified quality parameters. The term NSQ is defined under Section 16(1)(a) of the Drugs and Cosmetics Act, 1940. However, according to the Health Ministry, “the failure is specific to the drug products of the batch tested by the Government Laboratory and does not warrant concerns about other drug products available in the market.” The ministry added that the identification of NSQ and spurious medicines is undertaken regularly (monthly), in collaboration with state regulators, to ensure such drugs are detected and removed from the market. By Online Bureau ,

AcquisitionDrug Approval

100 Deals associated with Albendazole

External Link

KEGG	Wiki	ATC	Drug Bank
D00134	Albendazole	P02CA03	DB00518

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Echinococcosis	United States	Impax Laboratories LLC	11 Jun 1996
Neurocysticercosis	United States	Impax Laboratories LLC	11 Jun 1996
Cystitis	Japan	GlaxoSmithKline KK	19 Jan 1994
Helminthiasis	China	Hubei Huazhong Pharmaceutical Co. Ltd.	01 Jan 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 3	United States	Smithkline Beecham	31 Aug 2001
Microsporidiosis	Phase 3	United States	Smithkline Beecham	31 Aug 2001
Protozoan Infections	Phase 3	United States	Smithkline Beecham	31 Aug 2001
Intestinal Diseases	Phase 1	India	GSK Plc	21 Aug 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04410406 (CTgov)	Phase 3	Elephantiasis, Filarial	164	Albendazole+Ivermectin (IA (Ivermectin + Albendazole))	xfvcsaqsez = hbnpfebypc rgxjgcdipw (akdecejupt, rgitxcryqx - uaupfmiubj) View more	-	29 Jan 2026
				Albendazole+Moxidectin (MoxA (Moxidectin + Albendazole))	xfvcsaqsez = ojnjuaoojl rgxjgcdipw (akdecejupt, wigdyuxkdl - jkjnergzaa) View more
NCT03014167 (DeWorm3, CTgov)	Phase 3	Filariasis \| Growth hormone deficiency	357,716	albendazole (Community-wide Deworming (Intervention))	azgjadnkrg = xwryulbevy hsofowkbnh (irppicolfo, wbbmnvarvy - vosewpognk) View more	-	22 Jan 2026
				albendazole (School-age-targeted Deworming (Control))	azgjadnkrg = fihatexmjh hsofowkbnh (irppicolfo, bomhkacnph - gfpnukhtty) View more
NCT04966702 (BOHEMIA, Pubmed \| EClinicalMedicine)	Phase 3	Malaria	22,724	Ivermectin to all eligible humans	ptnzofngin(srszsevtmt): IRR = 1.29 (95.0% CI, 0.62 - 2.68)	Negative	01 Dec 2025
				Ivermectin to eligible humans plus injectable ivermectin to all eligible pigs and cattle
NCT05124691 (ALIVE, CTgov)	Phase 2/3	Trichuriasis \| Intestinal Helminthiasis	1,001	Albendazole	cmventpxye = vluccffpbw blztporsit (ageliscesa, bamlskvykp - nawvtfrxyg) View more	-	22 Sep 2025
NCT06184399 (Iverped, CTgov)	Phase 2	Trichuriasis \| Hookworm Infections \| Ascariasis	260	Placebo Ivermectin ODT+Albendazole 400 mg Oral Tablet (Arm A: Ivermectin ODT Placebo & Albendazole)	issvlttain = gkghlqjrhu arhhrvlsyk (lzhziogkep, ofqyyqqsnq - emwvkxntes) View more	-	22 Sep 2025
				Albendazole 400 mg Oral Tablet+Ivermectin 1.5 mg ODT (Arm B: Ivermectin ODT 100 µg/kg & Albendazole)	issvlttain = crfwaiqtwy arhhrvlsyk (lzhziogkep, xxqskewerc - xaybvulbrq) View more
NCT06188715 (Moxiped, CTgov)	Phase 3	Trichuriasis \| Hookworm Infections \| Ascariasis	224	Albendazole 400 mg Oral Tablet+Moxidectin 2 mg Oral Tablet (Arm A: Moxidectin 4/8 mg & Albendazole)	fmhagdclfq = bfxinayttd kocgxaqewe (bskhwnzzoi, uejtkwopkr - fbvjcegmev) View more	-	19 Sep 2025
				Placebo Mox+Albendazole 400 mg Oral Tablet (Arm B: Albendazole)	fmhagdclfq = hijkncthiw kocgxaqewe (bskhwnzzoi, kfmltuxpxb - ebemfltprq) View more
NCT04966702 (BOHEMIA, Pubmed \| N Engl J Med)	Phase 3	Malaria	28,932	Ivermectin (monthly administration for 3 consecutive months)	cxtvulghgq(xrrzemdase) = xjdyuvqdye pjmyifperf (idevbugakx )	Positive	24 Jul 2025
				Albendazole (active control)	cxtvulghgq(xrrzemdase) = opwjanczcj pjmyifperf (idevbugakx )
NCT06201559 (CTgov)	Phase 1	Intestinal Diseases	70	Albendazole (Albendazole IP 400 mg/400mg - Test 1 (T1))	jnqqdzizbm(ldvhdbjeji) = tqvbgtdqxk vnmfnivoau (hgoeonahpy, 114.1) View more	-	27 Jan 2025
				Albendazole (Albendazole IP 400 mg/400 mg - Test 2 (T2))	jnqqdzizbm(ldvhdbjeji) = hkqkfnheub vnmfnivoau (hgoeonahpy, 110.9) View more
NCT04700423 (CTgov)	Phase 2/3	Trichuriasis \| Hookworm Infections \| Ascariasis ... View more	536	albendazole+moxidectin (A: Moxidectin (8 mg) / Albendazole (400 mg))	ygfjkofvwd(mwjixxrlsf) = brcntlvgns ivgjcjtdya (lecskufxsw, wxyraqufsq - rtdhzoltzx) View more	-	05 Dec 2024
				albendazole+ivermectin (B: Ivermectin (200 µg/kg) / Albendazole (400 mg))	ygfjkofvwd(mwjixxrlsf) = rqozkynwvs ivgjcjtdya (lecskufxsw, ncbzfotbxn - oaoiresmai) View more
NCT04326868 (Pubmed \| Antimicrob Agents Chemother)	Phase 4	Infectious Diseases	-	Albendazole 400 mg	goalxalkmo(fkscumcqyx) = osekyrhknb owzsyiakyt (uoarawjrvf, 58 - 81) View more	-	02 Apr 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis